Читать книгу Experimental Design and Statistical Analysis for Pharmacology and the Biomedical Sciences - Paul J. Mitchell - Страница 10

Dr Paul J Mitchell is a Senior Lecturer and an Associate Professor in the Department of Pharmacy and Pharmacology, University of Bath, United Kingdom, and Adjunct Lecturer in the Department of Pharmacology and Therapeutics, National University of Ireland (NUI), Galway, Ireland.

His career in pharmacology started in 1975 when he joined the cardiovascular group led by Dr Bob Poyser at Beecham Pharmaceuticals, Harlow, United Kingdom. After five years, during which he also graduated with an Upper Second BSc in Applied Biology (Pharmacology) from North East London Polytechnic under Prof Geof B West, he transferred to the CNS disorders group led by Dr Mike Clarke. Dr Mitchell left Beecham in 1985 to start post‐graduate studies with Dr (now emeritus Prof) Peter Redfern in the School of Pharmacy and Pharmacology, University of Bath, United Kingdom. After successfully defending his PhD thesis on the Effect of Antidepressant Treatment on Social Behaviour and Circadian Rhythms of Locomotor Activity in the Rat in 1989, he joined the research laboratories of Wyeth‐Ayerst, Taplow, principally to examine the potential antidepressant activity of novel psychotropic compounds in the rodent models of social behaviour that were developed during his postgraduate studies. The results of these behavioural studies were pivotal in the company's decision to fully develop venlafaxine (known in‐house as Wy 45030) to the clinic. Subsequently, Dr Mitchell became heavily involved in the further pre‐clinical development of venlafaxine (Effexor®, Efexor®), the world's first SNRI antidepressant drug, which was approved by the U.S.FDA in 1993 and by the MHRA in the United Kingdom in 1994.

In 1995, Dr Mitchell returned to the University of Bath to set up his own lab to continue examining the effect of antidepressant drugs on rodent social behaviour (Resident‐Intruder test and Social Hierarchy model of social behaviour), while working very closely with the pharmaceutical industry (principally colleagues at Wyeth‐Ayerst in the USA, Lundbeck in Denmark, and Organon in the United Kingdom).

Over the last 25 years, Dr Mitchell has collaborated with colleagues at the University of Bath and NUIGalway to develop a coherent strategy to teach experimental design and statistical analysis to undergraduate and postgraduate students across subject areas in the Life and Biomedical sciences.

Dr Mitchell has been a member of the British Pharmacological Society since 1985. He is currently working closely with the society on a residential training workshop on the topic of this book covering the principles of robust, rigorous, experimental design, and statistical analysis. This course is ideal for early career researchers working in drug discovery or academia.